Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Hold” from Brokerages

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been assigned a consensus rating of “Hold” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $7.75.

A number of analysts have recently issued reports on the company. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th.

Bausch Health Companies Price Performance

NYSE BHC opened at $7.47 on Friday. The company’s 50 day simple moving average is $8.33 and its two-hundred day simple moving average is $7.28. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The stock has a market capitalization of $2.70 billion, a PE ratio of -15.56 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the business posted $1.03 earnings per share. The firm’s revenue was up 12.2% compared to the same quarter last year. On average, research analysts anticipate that Bausch Health Companies will post 3.74 EPS for the current year.

Institutional Investors Weigh In On Bausch Health Companies

Hedge funds have recently made changes to their positions in the business. Bfsg LLC grew its holdings in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after purchasing an additional 3,643 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Bausch Health Companies by 6.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock valued at $423,000 after buying an additional 3,923 shares during the last quarter. Tobam grew its stake in shares of Bausch Health Companies by 48.9% during the second quarter. Tobam now owns 26,148 shares of the company’s stock valued at $182,000 after buying an additional 8,586 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Bausch Health Companies by 3.9% in the second quarter. Van ECK Associates Corp now owns 302,471 shares of the company’s stock worth $2,108,000 after buying an additional 11,379 shares during the period. Finally, CIBC Asset Management Inc lifted its stake in shares of Bausch Health Companies by 8.8% in the 2nd quarter. CIBC Asset Management Inc now owns 373,647 shares of the company’s stock valued at $2,604,000 after acquiring an additional 30,124 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.